Clairity | BiotechTV

top of page

CLAIRITY BREAST, an AI platform that predicts five-year breast cancer risk from routine mammograms, became the first such AI tool to receive FDA authorization for breast cancer prediction

CEO Leff Luber describes the tool, which is mean to augment a radiologist's analysis, and how its modeling algorithm takes into account...

Company News

Jun 11

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.

Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.

Learn more about Evaluate

bottom of page

CLAIRITY BREAST, an AI platform that predicts five-year breast cancer risk from routine mammograms, became the first such AI tool to receive FDA authorization for breast cancer prediction

Follow BiotechTV

Sponsors

Sponsor Spotlight